DRUG QUANTITY MANAGEMENT POLICY - PER DAYS

POLICY: Topical Corticosteroids – Triamcinolone Spray Drug Quantity Management Policy – Per

Days

• Kenalog[®] (triamcinolone 0.147 mg/g spray – Sun, generic)

REVIEW DATE: 12/02/2022

OVERVIEW

Triamcinolone spray, a high-potency topical corticosteroid, is indicated for the relief of the inflammatory and pruritic manifestations of **corticosteroid-responsive dermatoses**.¹ Example of corticosteroid-responsive dermatoses include plaque psoriasis and atopic dermatitis.

Dosing

Triamcinolone 0.147 mg/g spray may be applied three or four times daily. Triamcinolone spray is a high-potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks of initial treatment. Treatment beyond two consecutive weeks may be indicated if there is no observed improvement.

Availability

Triamcinolone spray is available in 63 g and 100 g aerosol cans.¹ Each gram of spray contains 0.147 mg of triamcinolone acetonide. A 2-second application will cover an area approximately the size of the hand and delivers up to 0.2 mg triamcinolone acetonide.

Coverage is limited to an initial quantity sufficient to allow for a 2-week treatment course per 28 days at retail or a 6-week treatment course per 84 days at home delivery, if the patient is applying triamcinolone spray to an area approximately the size of two hands at maximum recommended weekly doses based on available package size.

POLICY STATEMENT

This Drug Quantity Management program has been developed to prevent stockpiling, misuse, and/or overuse of topical triamcinolone spray. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Package Size	Retail Maximum Quantity per 28 days	Home Delivery Maximum Qauntity per 84 days
Kenalog [®]	63 g can	126 g	378 g
(triamcinolone 0.147 mg/g spray, generic)	100 g can	100 g	300 g

Topical Corticosteroids – Triamcinolone DQM Policy – Per Days Page 2

CRITERIA

Approval of additional quantities of triamcinolone 0.147 mg/g spray (Kenalog, generic) is recommended if the patient is using the product for an FDA-approved indication and meets one of the following criteria:

Triamcinolone 0.147 mg/g spray (Kenalog, generic) 63 gram container

1. If the patient's condition has not sufficiently improved after the initial 2 weeks of treatment with triamcinolone spray, approve a one-time override for an additional quantity, not to exceed 126 grams at retail or 378 grams at home delivery, to allow for a total of 4 consecutive weeks of therapy at retail or 12 consecutive weeks of therapy at home delivery.

Triamcinolone 0.147 mg/g spray (Kenalog, generic) 100 gram container

1. If the patient's condition has not sufficiently improved after the initial 2 weeks of treatment with triamcinolone spray, approve a one-time override for an additional quantity, not to exceed 100 grams at retail or 300 grams at home delivery, to allow for a total of 4 consecutive weeks of therapy at retail or 12 consecutive weeks of therapy at home delivery.

EXCLUSIONS

Approval of additional quantities of triamcinolone 0.147 mg/g spray (Kenalog, generic) is NOT recommended in the following situations:

1. No overrides are recommended for use in any compounded formulations.

REFERENCES

1. Kenalog® spray, 0.147 mg/g [prescribing information]. Cranbury, NJ: Sun; November 2018.